PPAR-γ agonists: Therapeutic role in diabetes, inflammation and cancer

Trends in Pharmacological Sciences

Volumn 21, Issue 12, 2000, Pages 469-474

  Murphy, Gregory J ^a   Holder, Julie C ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; CELL NUCLEUS RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; CANCER; DRUG MECHANISM; DRUG USE; HUMAN; INFLAMMATORY DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW;

ANIMALS; DIABETES MELLITUS, TYPE 2; DNA-BINDING PROTEINS; HUMANS; INFLAMMATION; LIGANDS; NEOPLASMS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; THIAZOLES; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS;

EID: 0034406481     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-6147(00)01559-5     Document Type: Review

References (59)

1. Insulin resistance, impaired glucose tolerance and non-insulin-dependent diabetes, pathologic mechanisms and treatment: Current status and therapeutic possibilities
2. The triumvirate: β-cell, muscle, liver. A collusion reponsible for NIDDM
3. Thiazolidinediones: A new class of antidiabetic drugs
4. The steroid and thyroid hormone receptor superfamily
5. Ligand-independent activation domain in the N terminus of peroxisome-proliferator-activated receptor γ (PPAR-γ) - Differential activity of PPAR-γ-1 and -2 isoforms and influence of insulin
6. Interdomain communication regulating ligand binding by PPAR-γ
7. The nuclear receptor ligand-binding domain - Structure and function
8. Peroxisome proliferator-activated receptors: Nuclear control of metabolism
9. Activation of human aortic smooth-muscle cells is inhibited by PPAR-α but not by PPAR-γ activators
10. Oxidized LDL regulated macrophage gene expression through ligand activation of PPAR-γ
11. Expression of the peroxisome proliferator-activated receptor γ (PPAR-γ) in human atherosclerosis and regulation of macrophages by colony stimulating factors and oxidized low density lipoprotein
12. Novel sequence determinants in peroxosome proliferator signaling
13. The peroxisome proliferator-activated receptors at the cross-road of diet and hormonal signalling
14. Subtype- and response element-dependent differences in transactivation by peroxisome proliferator-activated receptors α and γ
15. PPAR-γ - Adipogenic regulator and thiazolidinedione receptor
16. Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor γ
17. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator activated receptor γ (PPARγ)
18. The structure-activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones
19. A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-γ reverses the diabetic phenotype of the Zucker diabetic fatty rat
20. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay
21. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ
22. PPAR-γ is required for the differentiation of adipose tissue in vivo and in vitro
23. PPAR-γ is required for placental, cardiac and adipose tissue development
24. PPAR-γ: An essential regulator of adipogenesis and modulator of fat cell function
25. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM
26. Influence of dietary fat composition on development of insulin resistance in rats
27. Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct but complementary mechanism relative to fibrates
28. Adipose expression of tumor necrosis factor-α: Direct role in obesity-linked insulin resistance
29. Thiazolidinediones block tumor necrosis factor a-induced inhibition of insulin signaling
30. Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat
31. Activators of peroxisome proliferator-activated receptor γ have depot-specific effects on human preadipocyte differentiation
32. Effect of troglitazone on body fat distribution in type 2 diabetic patients
33. Effect of troglitazone in insulin-treated patients with type 2 diabetes mellitus
34. Dominant negative mutations in human PPAR γ associated with severe insulin resistance, diabetes mellitus and hypertension
35. Obesity associated with a mutation in a genetic regulator of adipocyte differentiation
36. PPAR γ mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance
37. Troglitazone effects on gene expression in human skeletal muscle of type 2 diabetes involve up-regulation of peroxisome proliferatory-activated receptor-γ
38. PPAR-γ gene expression is elevated in skeletal muscle of obese and type II diabetic subjects
39. Troglitazone action is independent of adipose tissue
40. Pioglitazone-induced increase of insulin sensitivity in the muscles of the obese Zucker fa/fa rat cannot be explained by local adipocyte differentiation
41. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
42. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
43. PPAR-γ in monocytes - Less pain, any gain?
44. Macrophages in human atheroma contain PPAR-γ-differentiation-dependent peroxisomal proliferator-activated receptor-γ (PPAR-γ) expression and reduction of MMP-9 activity through PPAR-γ activation in mononuclear phagocytes in vitro
45. PPAR γ-ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells
46. Down regulation of peroxisome proliferator-activated receptor γ expression by inflammatory cytokines and its reversal by thiazolidinediones
47. A novel therapy for colitis utilizing PPAR-g ligands to inhibit the epithelial inflammatory response
48. Treatment of psoriasis with troglitazone therapy
49. Potent inhibitor effect of Troglitazone on carotid arterial wall thickness in Type 2 diabetes
50. Ligands for peroxisome proliferator-activated receptor-γ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice
51. Ligand for peroxisome proliferator γ (Troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo
52. Differentiation and reversal of malignant changes in colon cancer through PPAR-γ
53. Activation of the peroxisome proliferator-activated receptor γ promotes the development of colon tumors in C57BL/6J- APCMin/1 mice
54. Activators of the nuclear receptor PPAR-γ enhance colon polyp formation
55. PPAR-γ and colorectal carcinoma - Conflicts in a nuclear family
56. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-g ligand troglitazone in patients with liposarcoma
57. Peroxisome proliferator-activated receptor γ induces growth arrest and differentiation markers of human colon cancer cells
58. Loss-of-function mutations in PPAR γ associated with human colon cancer
59. Peroxosome proliferator-activated receptor γ ligands are potent inhibitors of angiogenesis in vitro and in vivo